These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 21748474)

  • 1. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
    Kadoglou NP; Sailer N; Kapelouzou A; Lampropoulos S; Vitta I; Kostakis A; Liapis CD
    Acta Diabetol; 2012 Aug; 49(4):269-76. PubMed ID: 21748474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
    Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
    Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adipokines: a novel link between adiposity and carotid plaque vulnerability.
    Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Gerasimidis T; Kostakis A; Liapis CD
    Eur J Clin Invest; 2012 Dec; 42(12):1278-86. PubMed ID: 23033969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes.
    Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Tsanikidis H; Vitta I; Karkos C; Karayannacos PE; Gerasimidis T; Liapis CD
    Exp Clin Endocrinol Diabetes; 2010 Feb; 118(2):75-80. PubMed ID: 19834878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk.
    Kadoglou NP; Vrabas IS; Kapelouzou A; Lampropoulos S; Sailer N; Kostakis A; Liapis CD
    Regul Pept; 2011 Oct; 170(1-3):57-61. PubMed ID: 21640762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis.
    Kadoglou NP; Fotiadis G; Lambadiari V; Maratou E; Dimitriadis G; Liapis CD
    Peptides; 2014 Jul; 57():12-6. PubMed ID: 24768795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
    Davidson MH; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Mazzone T; Carlson DM; Williams LA; Kelly MT; Camp HS; Lele A; Stolzenbach JC
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1298-306. PubMed ID: 24743431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease--KOZANI STUDY.
    Kadoglou NP; Lampropoulos S; Kapelouzou A; Gkontopoulos A; Theofilogiannakos EK; Fotiadis G; Kottas G
    Transl Res; 2010 May; 155(5):238-46. PubMed ID: 20403579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of type 2 diabetes and atorvastatin treatment on serum levels of MMP-7 and MMP-8.
    Kadoglou NP; Sailer N; Fotiadis G; Kapelouzou A; Liapis CD
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):44-9. PubMed ID: 24464597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease.
    Yu CM; Zhang Q; Lam L; Lin H; Kong SL; Chan W; Fung JW; Cheng KK; Chan IH; Lee SW; Sanderson JE; Lam CW
    Heart; 2007 Aug; 93(8):933-9. PubMed ID: 17344325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of physical activity with novel adipokines in patients with type 2 diabetes.
    Kadoglou NP; Vrabas IS; Kapelouzou A; Angelopoulou N
    Eur J Intern Med; 2012 Mar; 23(2):137-42. PubMed ID: 22284243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
    Lam HC; Chu CH; Wei MC; Keng HM; Lu CC; Sun CC; Lee JK; Chuang MJ; Wang MC; Tai MH
    Exp Biol Med (Maywood); 2006 Jun; 231(6):1010-5. PubMed ID: 16741040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia.
    Ferrer-García JC; Pérez-Silvestre J; Martínez-Mir I; Herrera-Ballester A
    Acta Diabetol; 2006 Nov; 43(3):75-8. PubMed ID: 17143784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia.
    Luo P; Li L; Wang LX; Zhu HH; Du S; Wu SL; Han YG; Wang GG
    Genet Mol Res; 2014 Apr; 13(2):2377-84. PubMed ID: 24737506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure.
    Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
    Adv Med Sci; 2008; 53(1):32-6. PubMed ID: 18635422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of low dose atorvastatin in diabetic dyslipidaemia.
    Pola P; Kumar R; Reddy AP; Rajagopal G; Harinarayan CV; Suresh V; Suchitra MM; Sachan A
    J Indian Med Assoc; 2009 Nov; 107(11):807-9. PubMed ID: 20469785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.